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  Abstract 
Background: Skin picking disorder (SPD) remains poorly understood with limited data regarding its underlying pathophysiology and 
appropriate treatment choices. One approach to refining our treatment of SPD might be to better understand the range of illness severity and 
the clinical associations with severity. 
Methods: 125 adults aged 18 to 65 with a primary, current DSM-5 diagnosis of SPD were assessed for the severity of their picking, using the 
Skin Picking Symptom Assessment Scale, and related mental health symptoms. To identify clinical and demographic measures associated 
with variation in disease severity, we utilized the statistical technique of partial least squares (PLS). 
Results: Greater SPD symptom severity was associated with higher Barratt attentional impulsiveness and motor impulsivity, higher Eysenck 
impulsivity, higher state anxiety/depression, having a current anxiety disorder, and having a lifetime substance use disorder. 
Conclusions: The present analysis is, to our knowledge, the most complete assessment of clinical variables and their relationship to illness 
severity in a sample of adults with SPD. Aspects of impulsivity and anxiety are both strongly associated with worse illness severity, and 
functional disability, in SPD. Treatment approaches should incorporate these as possible treatment targets when developing new treatment
 
approaches to this disorder.
 
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction 
Skin-picking  disorder  (SPD)  is  a  disabling,  
under-recognized condition in which individuals repeatedly 
pick at their skin, leading to noticeable tissue damage. Newly 
formalized in the 5th edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5), SPD has the 
following diagnostic criteria: recurrent picking resulting in 
skin lesions; repeated attempts to stop picking; and clinically Acknowledgment of Funding: Internal funds. 
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picking [1]. Psychosocial impediment, reduced quality of 
life, and medical problems such as infections are common 
among individuals with SPD [2–3]. 
Skin picking disorder remains poorly understood with 
limited data regarding its underlying pathophysiology and 
appropriate treatment choices [4]. There have been only five 
placebo-controlled trials of pharmacotherapy published for 
the treatment of SPD, and some have produced mixed 
results. Specifically, three of these studies examined 
selective serotonin reuptake inhibitors (SSRIs), with one 
(citalopram) exhibiting no difference from placebo, one 
(fluoxetine) demonstrating superiority to placebo, and one 
(fluoxetine) differentiating itself from placebo on a single 
outcome measure [5–7]. A single study reported significant 
benefits from the glutamate modulator n-acetyl cysteine 
versus placebo [8], whereas another study found that 
lamotrigine did not differentiate from placebo overall 
(though it possibly helped in a subset of patients with 
impaired cognitive flexibility) [9]. 
In terms of psychotherapy studies, there have been three 
randomized studies, one of a brief cognitive–behavioral 
therapy (CBT) intervention [10], one comparing habit rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 
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 reversal to wait-list [11], and a third study comparing 
self-help versions of habit reversal training (HRT) decou­
pling [12]. Although CBT and HRT appear promising, data 
are still lacking regarding optimal treatment duration and 
who with SPD  would benefit  most  from  which
psychotherapy. 
One approach to refining our treatment of SPD might be 
to better understand the range of illness severity and the 
clinical associations with severity. The DSM-5 criteria 
stipulate the minimal level of severity to meet diagnostic 
threshold (i.e. repeated behavior with resulting skin lesions) 
but do not provide details about severity levels and whether 
those can be meaningful in terms of treatment approaches. 
Thus the goal of this study was to identify clinical and 
demographic measures associated with variation in disease 
severity in a large sample of adults with SPD. Given the 
associations between impulsivity and skin picking [4], we
hypothesized that greater skin picking symptom severity 
would be associated with a greater degree of impulsivity. 2. Methods 
2.1. Subjects 
Men and women aged 18 to 65 with a primary, current 
DSM-5 diagnosis of SPD were recruited by newspaper 
advertisements and referrals for neuroimaging or treatment 
studies. Exclusion criteria included: 1) unstable medical 
illness; 2) history of seizures; 3) lifetime history of bipolar 
disorder, dementia, or psychotic disorder; 4) current (past 
3 months) substance use disorder; 5) current risk of suicide 
(defined as endorsing any symptom on the Columbia Suicide 
Severity Scale) [13]; and 6) current pregnancy or inadequate 
contraception in women of childbearing potential. 
Data were collected from September 2011 to June 2012 at 
the University of Minnesota and then from December 2012 
to the present time at the University of Chicago. The 
Institutional Review Boards for the University of Minnesota 
and the University of Chicago approved the studies and the 
informed consent procedures. After complete description of 
the studies and an opportunity to ask questions, participants 
provided written informed consent. This research was carried 
out in accordance with the principles of the Declaration of 
Helsinki. IND 108195 was assigned by the FDA. 2.2. Assessments 
Demographics and clinical features of SPD were assessed 
with a semi-structured interview. The semi-structured 
interview included proposed diagnostic criteria for SPD as 
well as questions regarding the phenomenology of picking. 
After the publication of the DSM-5, all subjects were 
retrospectively assessed based on case notes, and all clearly 
met full diagnostic criteria. Race/ethnicity was defined by 
the study subjects and was included to learn more about this variable in SPD. Psychiatric comorbidity was assessed using 
the Structured Clinical Interview for DSM-IV (SCID) [14]. 
All participants were assessed for the severity of their 
picking and related mental health symptoms. The severity of 
SPD was assessed using the self-report Skin Picking 
Symptom Assessment Scale (SP-SAS) [15]. The SP-SAS 
is a self-report scale that has satisfactory test-retest reliability 
and satisfactory change over time [15]. The SP-SAS is 
scored from 0 to 24, with higher scores indicative of greater 
symptom severity. 
Psychosocial functioning and depressive and anxiety 
symptoms were further assessed using the following valid 
and reliable measures: the patient-administered Sheehan 
Disability Scale (SDS) [16] and the clinician-administered 
Hamilton Anxiety Rating Scale (HAM-A) [17], and the 
clinician-administered Hamilton Depression Rating Scale 
(HAM-D) [18]. 
In addition, to examine impulsivity, each participant 
completed the Barratt Impulsiveness Scale 11 (BIS) [19] and 
the Eysenck Impulsiveness Questionnaire (EIQ) [20]. The 
BIS is a 30 question self-report measure that is designed to 
assess various aspects of impulsivity, yielding three total 
scores: attentional impulsivity, motor impulsivity, and 
non-planning impulsivity. The EIQ is a 54 question 
self-report measure comprised of three subscales: impulsiv­
ity, venturesomeness, and empathy. 
2.3. Cognitive assessments 
Cognitive assessments consisted of two previously 
validated tests taken from CANTABeclipse software. The 
choice of cognitive challenges was based on the clinical 
features of SPD. Previous research has found that individuals 
with SPD often exhibit significant deficits of motor 
inhibition and cognitive flexibility compared to healthy 
controls [21]. All testing was conducted in the same 
controlled environment to minimize confounding variables 
across subjects. The order of the tasks was fixed. 
Cognitive flexibility, i.e., set-shifting, was measured 
using the using the Intra-dimensional/Extra-dimensional 
Shift Task (IED task) [22]. On the task, subjects were 
presented with two stimuli on-screen for each trial, and 
attempted to learn an underlying ‘rule’ about which stimulus 
was correct. After selecting a stimulus, the computer 
provided feedback as to whether the choice was right or 
wrong. Through this feedback, participants attempted to 
learn underlying rules. Once they had identified the 
underlying rule, the task changed the rule, in order to 
measure the ability of the person to exhibit flexible 
responding. Key outcome measure was the total number of 
errors made on the extra-dimensional shift stage (the key 
stage when high level cognitive flexibility is measured). 
The stop-signal task (SST) was used to assess motor 
inhibition [23]. On this task, participants were instructed to 
respond to left- or right-facing arrows which appeared on a 
computer screen, one per time, in a rapid fashion. When an 
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ig. 1. Predictive residual sum of the squares (PRESS) as a function of the 
umber of latent factors. 
 auditory ‘stop-signal’ (beep) occurred, participants 
attempted to suppress their motor response for that given 
trial. By varying the time between the arrow presentation and 
the stop-signal, the task estimated the time taken by the 
individual to suppress a pre-potent response, referred to as 
the stop-signal reaction time. Median response times for go 
trials were also recorded, as a measure of general 
psychomotor speed. 
2.4. Data analysis 
To identify clinical and demographic measures associated 
with variation in disease severity, we utilized the statistical 
technique of partial least squares (PLS) [24–27]. PLS is a 
multivariate, iterative technique that constructs one or more 
latent factors (referred to as PLS components) that optimally 
explain variation in X and Y. The Y variable was total score on 
the SP-SAS and X variables were as follows: age, educational 
level, gender, age at first diagnosis, past treatment for SPD, 
history of grooming disorder or substance use disorder in one 
or more first-degree relatives, current smoking status (smoker 
or non-smoker), Hamilton Anxiety and Depression scale total 
scores, picking from multiple sites, presence of major 
depressive disorder, presence of any anxiety disorder, presence 
of any substance use disorder, presence of body dysmorphic 
disorder, presence of OCD, presence of ADHD, Barratt 
impulsiveness subscale scores (attentional, non-planning, and 
motor), Eysenck scores (impulsivity, empathy, venturesome­
ness), extra-dimensional set-shifting errors, and stop-signal 
reaction times (SSRTs). Unlike traditional regression, PLS is 
ideal in situations in which variables are correlated with each 
other; and when the number of variables is large in comparison 
to the number of cases, as was the case here [24–27]. Analysis  
was conducted using JMP Pro software Version 13.0. Any 
missing data points were imputed automatically by JMP using 
study means. The PLS model was fitted using leave-one-out 
cross-validation (non-linear iterative partial least squares, 
NIPALS algorithm), and the optimal number of latent factors 
was selected by minimizing the predictive residual sum of the 
squares (PRESS). X variables significantly contributing to the 
model (i.e. explaining significant variance in disease severity) 
were identified on the basis of 95% confidence intervals for 
bootstrap distribution of the standardized model coefficients 
not crossing zero (N = 1000 bootstraps). To confirm or refute 
the clinical relevance of the PLS model, we examined whether 
latent factor score(s) on the model correlated significantly with 
Sheehan Disability scores across all participants. 3. Results 
A total sample of 125 participants (mean age = 34.1 ± 
standard deviation 11.9 years; 87.2% female) were recruited. 
The participants reported a mean age at the onset of SPD of 
12.9 (9.0) years. Most (92 [73.6%]) participants picked skin 
from multiple sites. The mean score on the SP-SAS was 28.7 
(6.7) [range 13 to ×36] and the mean SDS score was 11.4 F
n(6.7) [range 0 to 28]. Depression and anxiety symptoms were 
fairly low with mean scores on the (HAM-A) and (HAM-D) 
4.4 (3.7) [range 0 to 20] and 4.6 (3.9) [range 0 to 21], 
respectively. 
Cross-validation showed that the optimal fit PLS model to 
minimize PRESS had one latent variable (Fig. 1) and hence 
this model was selected. This model accounted for total 9.6% 
of the variation in the clinical/demographic measures, and 
25.5% of variation in disease severity (SP-SAS total scores). 
The standardized model coefficients for each variable of 
interest are presented in Table 1. Variables with positive 
coefficients had a positive relationship with SP-SAS total 
scores, and vice versa. Those measures shown in bold and with 
an asterisk retained statistical significance by bootstrap, i.e. the 
95% confidence interval of the bootstrap distribution of the 
model coefficient did not cross zero (Fig. 2). Thus, higher SPD 
symptom severity was associated with higher Barratt atten­
tional and motor impulsivity, higher Eysenck impulsivity, 
higher state anxiety/depression, having a current anxiety 
disorder, and having a lifetime history of substance use 
disorder. Both X and Y PLS scores correlated significantly and 
positively with functional impairment on the Sheehan 
Disability Scale across all participants (Spearman's r = 0.2,
p = 0.03; and r = 0.50,  p b 0.001 respectively). 4. Discussion 
To our knowledge, this is the first study to examine the 
clinical correlates of illness severity in a large sample of 
adults with SPD. There were several important findings from 
this analysis, which was conducted using the statistical 
methodology of partial least squares (PLS), which best 
explained the co-variation between demographic/clinical 
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Table 1
 
Standardized model coefficients for each X variable of interest in the optimal PLS model (one latent variable). *: statistically significant predictive variable by bootstrap.
 
Coefficient SP-SAS 
Total 
BIS Attentional impulsivity * 0.1384 
HAM-A Total * 0.1075 
EIQ Impulsivity * 0.0956 
HAM-D Total * 0.0890 
Any anxiety disorder * 0.0791 
BIS Motor impulsivity * 0.0772 
Lifetime AUD/SUD * 0.0746 
Pick from multiple sites 0.0804 
IED Errors (block 8) 0.0789 
Family history of grooming disorder 0.0752 
BDD 0.0744 
EIQ Empathy 0.0649 
OCD 0.0613 
ADHD 0.0572 
Educational level 0.0516 
Major Depressive Disorder 0.0372 
EIQ Venturesomeness 0.0263 
Age 0.0235 
Past Treatment for SPD 0.0083 
Trichotillomania 0.0076 
Intercept 0.0000 
Age at Diagnosis -0.0043 
BIS non-planning impulsivity -0.0133 
Gender -0.0134 
SST SSRT -0.0191 
Current Smoker -0.0224 
Family history of substance use disorder -0.0684 
ig. 2. Distribution of PLS X and Y scores across individuals in the study. measures and symptom severity by constructing a single 
latent factor from the data. Aspects of impulsivity (specif-
ically domains of the BIS and the EIQ) were significantly 
and positively associated with illness severity, as were 
co-occurring history of substance addiction and elevated 
state symptoms of anxiety and depression. Crucially, we 
demonstrated that higher scores on the latent PLS component 
were significantly correlated with greater impairment on the 
Sheehan Disability Scale, confirming that the model was 
clinically relevant. One important point is that only certain 
aspects of impulsivity were positively correlated, not all 
types of impulsivity (for example, certain domains of the BIS 
and EIQ, as well as categorical ADHD and the cognitive 
measure of the SST were not significant in the PLS model). 
Secondly, no measure of compulsivity was significantly 
associated with illness severity in the model (that is, the IED 
block 8 errors and categorical OCD). Finally, although 
depressive symptoms were correlated with severity, rates of 
categorical major depressive disorder were not, though this 
may reflect the relative scarcity of clinical depression in the 
cohort. 
Taken together, these data suggest that very specific 
clinical variables are associated with illness severity in SPD, 
and as such, may represent useful and specific targets for 
treatment interventions. The domains of attentional and 
motor impulsivity on the BIS were robustly associated with 
illness severity. Attentional impulsivity is characterized by 
the ability to sustain attention on a given task (for example, “I don't ‘pay attention’”), whereas motor impulsivity is 
related to the ability to control behavioral (for example, “I act 
on ‘impulse’”). The association with substance use disorders 
may also be related to these impulsivity constructs. These 
may be appropriate targets for cognitive behavioral therapy 
or even cognitive rehabilitation using specific computer 
tasks focusing on these particular cognitive domains of 
interest. Similarly, the centrality of impulsive measures in F
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 explaining variation in symptom severity in SPD suggests 
that medications capable of treating impulsivity would be 
worth exploring in clinical trials. For example, there have 
been no blinded trials of stimulant medication in SPD to 
date. Although the treatment of the picking alone may be 
sufficient to address some comorbid findings, the question 
arises as to whether simultaneously treating co-occurring 
substance use, for example, may be useful in decreasing the 
symptoms of SPD. 
One surprising finding was that the BIS measurement of 
motor impulsivity showed significant associations with symp­
tom severity while the SST did not. This seems contradictory to 
a previous report that SST was significantly different in adults 
with SPD compared to controls [28]. This discrepancy may be 
explained by the fact that the SST represents a trait marker that 
characterizes SPD but that it has no relationship to illness 
severity, whereas the BIS does. Alternatively, this discrepancy 
between the two measures may indicate that the concept of 
“motor impulsivity” is multidimensional and requires a more 
detailed understanding of motor impulsivity and its neurobio­
logical underpinnings than relying on one laboratory-based 
measure that may be reductionist. 
The present findings emphasize the importance of 
refining our subtyping of impulsivity. If researchers are 
able to specify the specific nature of impulsivity within 
people with SPD, clinicians may be able to design treatment 
plans that are specifically adapted to manage problems 
resulting from that particular form of impulsivity. 
Anxiety symptoms and anxiety disorders were both 
positively associated with illness severity in this study. 
This seems consistent with previous research that has found 
high rates of anxiety disorders among those with SPD and 
has found that picking is often triggered by and in turn 
alleviates feelings of anxiety [29–31]. These  findings
provide further evidence that anxiety and picking may 
reflect a complex cycle of behavior and that approaches to 
anxiety alone may not be enough to eliminate picking but 
that treatment which ignores anxiety may be less effective. 
Although this study represents a potentially beneficial 
approach to understanding SPD, there exist several limita­
tions. Our approach of defining the statistical significance of 
individual measures in the PLS model by using bootstrap is 
quite conservative and so some variables may have been 
overlooked (false negatives). However, this approach does 
mean that one can have a high degree of statistical 
confidence in the significant results (low risk of false 
positive error). As with any such study, the current data 
cannot show that the findings would generalize to SPD 
patients presenting in other settings such as to family 
doctors. The proportion of variance accounted for was 
relatively modest and other unmeasured variables are likely 
to be important in being associated with disease severity. 
Genetic polymorphisms, information on upbringing/child­
hood trauma, as well as a broader range of biological 
measures (e.g. neuroimaging parameters) may all be 
valuable for future studies to consider. The present analysis is, to our knowledge, the most 
complete assessment of clinical variables and their relation­
ship to illness severity in a sample of adults with SPD. 
From these findings, it seems that aspects of impulsivity 
and anxiety are both strongly associated with worse illness 
severity, and functional disability, in SPD. As such, 
treatment approaches should incorporate these as possible 
treatment targets when developing new treatment approaches 
to this disorder. References 
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